PROTEINSEQ

"Sensitive, specific high-throughput plasma proteome analysis via ProteinSeq"

Coordinatore	UPPSALA UNIVERSITET    more Spiacenti, non ci sono informazioni su questo coordinatore. Contattare Fabio per maggiori infomrazioni, grazie.
Nazionalità Coordinatore	Sweden [SE]
Totale costo	2˙499˙600 €
EC contributo	2˙499˙600 €
Programma	FP7-IDEAS-ERC Specific programme: "Ideas" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
Code Call	ERC-2011-ADG_20110310
Funding Scheme	ERC-AG
Anno di inizio	2012
Periodo (anno-mese-giorno)	2012-03-01   -   2017-02-28

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	UPPSALA UNIVERSITET  Organization address address: SANKT OLOFSGATAN 10 B city: UPPSALA postcode: 751 05 contact info Titolo: Ms. Nome: Birgitta Cognome: Gustafsson Email: send email Telefono: +4618471 5029 Fax: +4618471 5077	SE (UPPSALA)	hostInstitution	2˙499˙600.00
2	UPPSALA UNIVERSITET  Organization address address: SANKT OLOFSGATAN 10 B city: UPPSALA postcode: 751 05 contact info Titolo: Prof. Nome: Dag Ake Ulf Cognome: Landegren Email: send email Telefono: +46 18 471 4910 Fax: +46 18 471 4808	SE (UPPSALA)	hostInstitution	2˙499˙600.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'Despite increasing interest in biomarkers to diagnose and distinguish diseases and select treatment few new protein biomarkers are being successfully validated. Important explanations for the limited success are poor specificity and sensitivity of detection of plasma proteins using current assays, and inability to analyze large numbers of markers and samples. Improved assays should provide access to plasma protein biomarkers at levels below current detection thresholds, potentially reflecting disease processes anywhere in the body at early stages. They should also distinguish closely similar protein variants. The assays should furthermore assess numerous markers in parallel with limited consumption of biobank samples. The aim of this project is to enable investigations of protein biomarkers at entirely new levels of performance. The basis of the proposal is our expertise in molecular tools and specifically an approach to protein analysis that addresses the above requirements. This technology is now ready to be scaled for large-volume, high-performance assays with the following characteristics: 1) Unsurpassed specificity via simultaneous detection of three epitopes on any target protein. 2) Amplifiable DNA strands form upon specific detection, permitting ultrasensitive detection. 3) Only appropriate reagent combinations result in amplifiable reporter strands, overcoming obstacles to multiplex protein detection. 4) Tag sequences in the amplified DNA strands identify the detected proteins and the investigated samples, allowing digital information of protein abundance to be retrieved via next generation DNA sequencing of multiplex reactions for large numbers of patients in single runs. I propose to set up and apply assays of a thousand proteins in parallel in small plasma samples, and in a subproject I will target proteins on a novel and promising class of cancer biomarkers – exosomes. '